Encyprate
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Encyprate is a monoamine oxidase inhibitor (MAOI) agent that was developed for use in the treatment of depression. It is an irreversible inhibitor of the MAO enzyme because it is agent that can form covalent bonds with the active site. As such, it is sometimes referred to as a “suicide inactivator” of MAO. It was invented by Bruce Horrom of Abbott in the 1960s by structure activity studies on pargyline. Although it is not known to have ever been used in the clinic, it is an example of the heritage of agents that were developed at that time.
Encyprate is a monoamine oxidase inhibitor (MAOI) agent that was developed for use in the treatment of depression. It is an irreversible inhibitor of the MAO enzyme because it is agent that can form covalent bonds with the active site. As such, it is sometimes referred to as a “suicide inactivator” of MAO. It was invented by Bruce Horrom of Abbott in the 1960s by structure activity studies on pargyline. Although it is not known to have ever been used in the clinic, it is an example of the heritage of agents that were developed at that time. ==Synthesis== The condensation between cyclopropylamine [765-30-0] (1) and benzaldehyde [100-52-7] (2) gives N-benzylidenecyclopropylamine [3187-77-7] (3). The reduction of the Schiff-base gives N-benzylcyclopropylamine [13324-66-8] (4). Urethane formation with ethyl chloroformate [541-41-3] (5) completes the synthesis of encyprate (6).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329428057 under CC BY-SA 4.0; modifications have been made.